Apollomics Class A Stock Performance
| APLM Stock | 8.16 1.51 15.62% |
The firm shows a Beta (market volatility) of -2.03, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Apollomics are expected to decrease by larger amounts. On the other hand, during market turmoil, Apollomics is expected to outperform it. Apollomics Class A right now shows a risk of 14.75%. Please confirm Apollomics Class A potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Apollomics Class A will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Apollomics Class A has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very uncertain essential indicators, Apollomics may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
Five Day Return (18.40) | Year To Date Return (91.12) | Ten Year Return (99.18) | All Time Return (99.18) |
1 | Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology Congre... | 09/16/2024 |
2 | Apollomics Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split | 11/21/2024 |
3 | Apollomics Shares Scheduled to Reverse Split on Monday, November 25th | 11/22/2024 |
| Begin Period Cash Flow | 32.7 M |
Apollomics |
Apollomics Relative Risk vs. Return Landscape
If you would invest 1,200 in Apollomics Class A on August 30, 2024 and sell it today you would lose (384.00) from holding Apollomics Class A or give up 32.0% of portfolio value over 90 days. Apollomics Class A is currently generating 0.1643% in daily expected returns and assumes 14.746% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Apollomics, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Apollomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apollomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Apollomics Class A, and traders can use it to determine the average amount a Apollomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0111
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | APLM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.75 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.16 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Apollomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apollomics by adding Apollomics to a well-diversified portfolio.
Apollomics Fundamentals Growth
Apollomics Stock prices reflect investors' perceptions of the future prospects and financial health of Apollomics, and Apollomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apollomics Stock performance.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.63 | ||||
| Operating Margin | (14.32) % | ||||
| Current Valuation | (12.21 M) | ||||
| Shares Outstanding | 110.27 M | ||||
| Price To Book | 0.43 X | ||||
| Price To Sales | 4.28 X | ||||
| Revenue | 821 K | ||||
| EBITDA | (171.75 M) | ||||
| Net Income | (172.59 M) | ||||
| Total Debt | 4.66 M | ||||
| Book Value Per Share | 0.19 X | ||||
| Cash Flow From Operations | (43.21 M) | ||||
| Earnings Per Share | (0.15) X | ||||
| Market Capitalization | 16.52 M | ||||
| Total Asset | 55.39 M | ||||
| Retained Earnings | (646.97 M) | ||||
| Working Capital | 26.37 M | ||||
About Apollomics Performance
By examining Apollomics' fundamental ratios, stakeholders can obtain critical insights into Apollomics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Apollomics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.1 K | 711 | |
| Return On Tangible Assets | (4.25) | (4.46) | |
| Return On Capital Employed | (1.31) | (1.38) | |
| Return On Assets | (3.12) | (3.27) | |
| Return On Equity | (4.19) | (3.98) |
Things to note about Apollomics Class A performance evaluation
Checking the ongoing alerts about Apollomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apollomics Class A help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apollomics Class A had very high historical volatility over the last 90 days | |
| Apollomics Class A has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 821 K. Net Loss for the year was (172.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Apollomics generates negative cash flow from operations | |
| About 47.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Apollomics Shares Scheduled to Reverse Split on Monday, November 25th |
- Analyzing Apollomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apollomics' stock is overvalued or undervalued compared to its peers.
- Examining Apollomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apollomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apollomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apollomics' stock. These opinions can provide insight into Apollomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apollomics Class A. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.023 | Quarterly Revenue Growth 2.623 | Return On Assets (0.63) | Return On Equity (1.49) |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.